Biogen (BIIB) Akcija Kursas
Biogen Kursas
Pajamos augo 7,1 % per metus per pastaruosius 19 metus iki 9,89 mlrd. USD. Pelnas akcijai augo 14,9 % per metus per pastaruosius 19 metus. Biogen grynoji marža dabar yra 13,1 %, sumažėjo nuo 14,2 % prieš kelerius metus. Analitikų tikslinės kainos mediana yra 240,00 USD, t. y. žemiau dabartinę kainą 3,4 %. Iš 43 analitikų 29 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Biogen akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Biogen akcija ir akcijų analizė
Dažnai užduodami klausimai apie Biogen akciją
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analitikai šiuo metu nustato vidutinę Biogen akcijos tikslinę kainą 238,69 USD (mediana: 240,00 USD), t. y. −1,3 % palyginti su paskutine kaina. Konsensusas pagrįstas 43 analitikų reitingais.
43 analitikai šiuo metu vertina Biogen akciją: 29 rekomenduoja pirkti, 13 laikyti ir 1 parduoti. 2026 m. analitikai tikisi, kad Biogen gaus 10,45 mlrd. USD pajamų ir 12,42 USD pelno akcijai.
Pagal dabartinį kursą Biogen akcija kainuoja 221,61 EUR (248,57 USD).
Biogen akcija (BIIB) kotiruojama 11 biržose, įskaitant: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
tikėtina pelnas Biogen yra 10,45 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Biogen yra 1,83 mlrd. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Biogen šiuo metu yra 20,02. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Biogen akcijos vertę.
Kainų ir pardavimų santykis (KUV) Biogen šiuo metu yra 3,50. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Biogen akcijos įvertinimo metrika.
Eulerpool kokybės balas Biogen yra 3/10.
Biogen ISIN yra US09062X1037. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Biogen WKN yra 789617. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Biogen prekybos žymė yra BIIB. Ši biržos žymė naudojama Biogen akcijoms prekiauti biržoje.
Biogen akcija
Biogen Pagrindiniai konkurentai
Biogen Biržos simbolis
Biogen FIGI
Visos Biogen pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Biogen akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Biogen. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: